Read on Twitter
Special issue of EJSO @ejsotweets on peritoneal surface malignancies edited by @glehenolivier is out
Nice cover by @RENAPE_Network featuring the societies of the contributors (yes, we are on it!!)
Contains imp messages from PSOGI 2018 incl PSOGI guidelines on PMP &mesothelioma
Nice cover by @RENAPE_Network featuring the societies of the contributors (yes, we are on it!!)
Contains imp messages from PSOGI 2018 incl PSOGI guidelines on PMP &mesothelioma
Editorial
Peritoneal metastases management: Towards the era of prospective randomized trials? https://www.ejso.com/article/S0748-7983(20)30483-2/fulltext?dgcid=raven_jbs_etoc_email#.X-k0oW5lcSI.twitter
@SPeritoneum @RENAPE_Network @PMPSurvivor @acpmpresearch @europmp @ejsotweets
Peritoneal metastases management: Towards the era of prospective randomized trials? https://www.ejso.com/article/S0748-7983(20)30483-2/fulltext?dgcid=raven_jbs_etoc_email#.X-k0oW5lcSI.twitter
@SPeritoneum @RENAPE_Network @PMPSurvivor @acpmpresearch @europmp @ejsotweets
#psogiguidelines #PMP
Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment https://www.ejso.com/article/S0748-7983(20)30114-1/fulltext?dgcid=raven_jbs_etoc_email#.X-k1aV5Ge8c.twitter
@SPeritoneum @RENAPE_Network @PMPSurvivor @acpmpresearch @europmp @ejsotweets
Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment https://www.ejso.com/article/S0748-7983(20)30114-1/fulltext?dgcid=raven_jbs_etoc_email#.X-k1aV5Ge8c.twitter
@SPeritoneum @RENAPE_Network @PMPSurvivor @acpmpresearch @europmp @ejsotweets
#PSOGIguidelines #peritonealmesothelioma
Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up https://www.ejso.com/article/S0748-7983(20)30113-X/fulltext?dgcid=raven_jbs_etoc_email#.X-k1oukNF9U.twitter
@SPeritoneum @RENAPE_Network @ejsotweets
Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up https://www.ejso.com/article/S0748-7983(20)30113-X/fulltext?dgcid=raven_jbs_etoc_email#.X-k1oukNF9U.twitter
@SPeritoneum @RENAPE_Network @ejsotweets
Prehabilitation of patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy https://www.ejso.com/article/S0748-7983(20)30067-6/fulltext?dgcid=raven_jbs_etoc_email#.X-k1447XTPs.twitter
@SPeritoneum @RENAPE_Network @ejsotweets @DeliaCortesGuir
@SPeritoneum @RENAPE_Network @ejsotweets @DeliaCortesGuir
#peritonealMRI
Peritoneal MRI in patients undergoing cytoreductive surgery and HIPEC: History, clinical applications, and implementation https://www.ejso.com/article/S0748-7983(19)30303-8/fulltext?dgcid=raven_jbs_etoc_email#.X-k2Ehnd7O4.twitter
@SPeritoneum @RENAPE_Network @ejsotweets @ajthrower @MPEngbersen
Peritoneal MRI in patients undergoing cytoreductive surgery and HIPEC: History, clinical applications, and implementation https://www.ejso.com/article/S0748-7983(19)30303-8/fulltext?dgcid=raven_jbs_etoc_email#.X-k2Ehnd7O4.twitter
@SPeritoneum @RENAPE_Network @ejsotweets @ajthrower @MPEngbersen
A comparison of outcomes following total & selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian,FT & PP cancer– A study by INDEPSO https://www.ejso.com/article/S0748-7983(19)30304-X/fulltext?dgcid=raven_jbs_etoc_email#.X-k2PRF7fbI.twitter @SPeritoneum @ejsotweets @IJGConline @gyncsm @EJGOjournal
Phase II randomized study on tissue distribution and pharmacokinetics of cisplatin according to different levels of intra-abdominal pressure (IAP) during HIPEC (NCT02949791) https://www.ejso.com/article/S0748-7983(19)30516-5/fulltext?dgcid=raven_jbs_etoc_email#.X-k3G43bp8E.twitter
@ejsotweets @SPeritoneum @IJGConline @Bhandoria @BatistaTP
@ejsotweets @SPeritoneum @IJGConline @Bhandoria @BatistaTP
Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI) https://www.ejso.com/article/S0748-7983(20)30666-1/fulltext?dgcid=raven_jbs_etoc_email#.X-k3diXSWRo.twitter
@ejsotweets @SPeritoneum @hpb_so @me4_so
@ejsotweets @SPeritoneum @hpb_so @me4_so
Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer https://www.ejso.com/article/S0748-7983(19)30444-5/fulltext?dgcid=raven_jbs_etoc_email#.X-k4A2b8tL8.twitter @ejsotweets @SPeritoneum @GynMe4 @EJGOjournal @gyncsm @IJGConline @Bhandoria
Pharmacokinetics of the intraperitoneal nanoparticle pegylated liposomal doxorubicin in patients with peritoneal metastases https://www.ejso.com/article/S0748-7983(19)30380-4/fulltext?dgcid=raven_jbs_etoc_email#.X-k4JoyeW1w.twitter
@ejsotweets @SPeritoneum @WimCeelen
@ejsotweets @SPeritoneum @WimCeelen
A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: A phase I first in man study https://www.ejso.com/article/S0748-7983(19)30913-8/fulltext?dgcid=raven_jbs_etoc_email#.X-k4Sbs9wbo.twitter
@ejsotweets @SPeritoneum @PMPSurvivor @acpmpresearch @europmp
@ejsotweets @SPeritoneum @PMPSurvivor @acpmpresearch @europmp
#gastricPM
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer https://www.ejso.com/article/S0748-7983(20)30495-9/fulltext?dgcid=raven_jbs_etoc_email#.X-k4hui7-eo.twitter
@SPeritoneum @dr_mohammadyami @jeetrohila @ejsotweets
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer https://www.ejso.com/article/S0748-7983(20)30495-9/fulltext?dgcid=raven_jbs_etoc_email#.X-k4hui7-eo.twitter
@SPeritoneum @dr_mohammadyami @jeetrohila @ejsotweets
#PIPAC #UnresectablePM
Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy https://www.ejso.com/article/S0748-7983(19)30522-0/fulltext?dgcid=raven_jbs_etoc_email#.X-k4okilFcc.twitter @dr_mohammadyami @ejsotweets @SPeritoneum
Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy https://www.ejso.com/article/S0748-7983(19)30522-0/fulltext?dgcid=raven_jbs_etoc_email#.X-k4okilFcc.twitter @dr_mohammadyami @ejsotweets @SPeritoneum
ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis https://www.ejso.com/article/S0748-7983(19)30406-8/fulltext?dgcid=raven_jbs_etoc_email#.X-k5uxd6Cp0.twitter
@ejsotweets @SPeritoneum @WimCeelen
@ejsotweets @SPeritoneum @WimCeelen
